Transplant International

Cover image for Vol. 30 Issue 2

Edited By: Thomas Wekerle and Rainer Oberbauer

Impact Factor: 2.835

ISI Journal Citation Reports © Ranking: 2015: 12/25 (Transplantation); 40/200 (Surgery)

Online ISSN: 1432-2277

Featured

  • Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study

    Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study

    Virologic response over time. (a) On-treatment virologic response. (b) SVR12. Virologic response was assessed in randomized subjects at on-treatment weeks 2, 4, 8 and 12, and EOT. SVR was defined as HCV RNA <15 IU/ml (detectable or undetectable). HCV, hepatitis C virus; LLQ, lower limit of quantitation; EOT, end of treatment; SVR12, sustained virologic response 12 weeks after the end of treatment; CI, confidence interval; SMV, simeprevir; SOF, sofosbuvir; RBV, ribavirin. aArm 1, n = 11; Arm 2, n = 11; Arm 3, n = 11. bArm 1, n = 9; Arm 2, n = 10; Arm 3, n = 11. cFor the two subjects who did not achieve SVR12, one committed suicide and one had viral relapse.

  • Increased risk of graft failure and mortality in Dutch recipients receiving an expanded criteria donor kidney transplant

    Increased risk of graft failure and mortality in Dutch recipients receiving an expanded criteria donor kidney transplant

    Selection of patients and available cases in the analyses.

  • Orthotopic tracheal transplantation using human bronchus: an original xenotransplant model of obliterative airway disorder

    Orthotopic tracheal transplantation using human bronchus: an original xenotransplant model of obliterative airway disorder

    Development of obliterative airway disease after transplantation. (a) Comparative overview of the obliterative lesion observed in human bronchiolitis obliterans syndrome (BOS), Brown Norway (BN), and nude (RNU) models (trichrome staining, upper pictures). The fibroproliferative disorder seems to be more severe in the BN model (trichrome staining, lower pictures). (b) The composition of the epithelial coverage is reported in human BOS, BN, and RNU model (PAS staining). The physiological epithelium is highly preserved in human patients while it is absent in the BN group and accounts for less than 50% in the RNU group. C: cartilage; O: obliterative lesion.

  • The association between killer-cell immunoglobulin-like receptor (KIR) and KIR ligand genotypes and the likelihood of BK virus replication after kidney transplantation

    The association between killer‐cell immunoglobulin‐like receptor (KIR) and KIR ligand genotypes and the likelihood of BK virus replication after kidney transplantation

    The concept of NK cell activity and the “missing-self” hypothesis. Some of the inhibitory KIRs (such as KIR2DL1/2DL2/2DL3 and KIR3DL1/3DL2) recognize specific HLA major histocompatibility complex class I molecules (including HLA-A, HLA-B, HLA-C, and HLA-G) and thus inhibit cytotoxicity. Failure to recognize the appropriate KIR ligand on a mismatched cell triggers NK-cell-mediated cytotoxicity.

  • Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers

    Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers

    Kaplan–Meier curves for liver graft survival in HCV-negative recipients compared with HCV-positive ones divided into two groups according to HLA-DRB1*11 phenotype and IL-28B genotype. (a) At 10 years post-transplant. (b) At 1 year post-transplant. HCV, hepatitis C virus; HLA, human leukocyte antigen; IL-28B, interleukin-28B.

  • Clinical and microbiological epidemiology of early and late infectious complications among solid-organ transplant recipients requiring hospitalization

    Clinical and microbiological epidemiology of early and late infectious complications among solid‐organ transplant recipients requiring hospitalization

    Number of infectious-related hospitalizations per post-transplant time period and total rate by transplanted organ. (Note: For number of hospitalizations per 1000 transplant-days, the error bars represent 95% confidence intervals based on a Poisson distribution).

  • Donor risk indices in pancreas allocation in the Eurotransplant region

    Donor risk indices in pancreas allocation in the Eurotransplant region
  • New classification of donation after circulatory death donors definitions and terminology

    New classification of donation after circulatory death donors definitions and terminology

    Uncontrolled DCD process. No flow: Kidney ≤30 min; Liver ≤ 15 minCPR duration: ≥30 minNo-touch period: 2 min to 20 minTotal WIT: 120 min to 150 min

  • Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration

    Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration

    Approaches that may improve outcomes and decrease complications after vascularized composite allotransplantation (VCA).

  • Dynamic changes of B-cell compartments in kidney transplantation: lack of transitional B cells is associated with allograft rejection

    Dynamic changes of B‐cell compartments in kidney transplantation: lack of transitional B cells is associated with allograft rejection

    Gating strategy for the determination of human peripheral blood B lymphocyte subpopulations. (a) Definition of B cells via distribution profiles of SS/FS, CD45+, and CD19+. (b) Determination of mature naive cells as IgM+IgD+CD27− B cells. (c) Memory cells are defined by the expression of CD27+ and divided into IgM−CD27+ or IgM−CD21+ switched memory B cells and IgM+CD27+ or IgM+CD21+ nonswitched B cells. (d) Transitional B cells represent the CD24highCD38high subset with same corresponding population of IgMhighCD38high cells; plasmablasts are IgM−CD38high B cells or CD24−CD38high B cells.

  • Complement inhibition as potential new therapy for antibody-mediated rejection

    Complement inhibition as potential new therapy for antibody-mediated rejection

    Schematic illustration of classical complement activation and therapeutic strategies targeting complement. In a first step of the classical cascade, antibodies bound to HLA expressed on donor endothelial cells interact with C1q and stabilize the formation of the C1 complex (Ca2+ dependent). Active C1 subunit C1s cleaves factor C4 into C4a and C4b, the latter providing a binding site for C2 facilitating its cleavage by C1s into C2a and C2b. Under the control of complement-regulatory proteins and Factor I, surface-bound C4b is degraded to C4d. Capillary C4d staining has proven to be a useful diagnostic marker. If strong activation overwhelms these control mechanisms, surface-bound C4b2a becomes a stable, active C3 convertase that cleaves C3 into the anaphylatoxin C3a and C3b which again covalently binds to the surface. The combination of C4b2a with C3b forms the active C5 convertase (C4b2a3b) that can now cleave C5 into the anaphylatoxin C5a and C5b. C5b is responsible for the assembly of the membrane attack complex (MAC) which is inserted in the cell membrane. By stably binding to C5 in a 0.5:1 molar ratio of antibody to C5, eculizumab hinders its cleavage.

  • Clinical consequences of circulating CD28-negative T cells for solid organ transplantation

    Clinical consequences of circulating CD28-negative T cells for solid organ transplantation

    CD28-positive (CD28pos) memory T cells may become CD28 negative (CD28neg) under the influence of repetitive cell proliferation and cytomegalovirus (CMV) infection, which is further promoted by an inflammatory milieu and tumor necrosis factor-alpha (TNF-alpha). The defining characteristics of the CD4 and CD8 CD28neg T cells are shown on the right side. The CD8 CD28neg T cells contain suppressor cells (Tsup). NKR: natural killer receptor.

  • Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study
  • Increased risk of graft failure and mortality in Dutch recipients receiving an expanded criteria donor kidney transplant
  • Orthotopic tracheal transplantation using human bronchus: an original xenotransplant model of obliterative airway disorder
  • The association between killer‐cell immunoglobulin‐like receptor (KIR) and KIR ligand genotypes and the likelihood of BK virus replication after kidney transplantation
  • Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers
  • Clinical and microbiological epidemiology of early and late infectious complications among solid‐organ transplant recipients requiring hospitalization
  • Donor risk indices in pancreas allocation in the Eurotransplant region
  • New classification of donation after circulatory death donors definitions and terminology
  • Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration
  • Dynamic changes of B‐cell compartments in kidney transplantation: lack of transitional B cells is associated with allograft rejection
  • Complement inhibition as potential new therapy for antibody-mediated rejection
  • Clinical consequences of circulating CD28-negative T cells for solid organ transplantation

Recently Published Issues

See all

Transplant International Focus Issue Collection

Focus Issue Collection

Video Highlights

Watch the Video!

2013 IF



Please take a moment to view the videos in our Transplant International library where you will find valuable information and essential resources!


Innovations at Transplant International

SEARCH

SEARCH BY CITATION